MassMutual Private Wealth & Trust FSB Has $6.11 Million Holdings in Zoetis Inc. (NYSE:ZTS)

MassMutual Private Wealth & Trust FSB decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 5.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 37,522 shares of the company’s stock after selling 2,006 shares during the period. MassMutual Private Wealth & Trust FSB’s holdings in Zoetis were worth $6,113,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC acquired a new position in Zoetis in the 3rd quarter valued at approximately $31,000. First Personal Financial Services purchased a new position in shares of Zoetis during the 3rd quarter valued at $33,000. Capital Performance Advisors LLP acquired a new position in shares of Zoetis in the third quarter worth $33,000. Dunhill Financial LLC boosted its position in Zoetis by 80.6% during the third quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the last quarter. Finally, Quarry LP lifted its holdings in shares of Zoetis by 273.2% during the 2nd quarter. Quarry LP now owns 209 shares of the company’s stock valued at $36,000 after buying an additional 153 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Stock Performance

Shares of NYSE ZTS opened at $166.01 on Monday. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.53. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company has a market cap of $74.90 billion, a P/E ratio of 31.20, a P/E/G ratio of 2.51 and a beta of 0.89. The business’s 50 day moving average is $170.93 and its two-hundred day moving average is $179.98.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating the consensus estimate of $1.46 by $0.12. The firm had revenue of $2.40 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The business’s quarterly revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.36 EPS. On average, equities analysts expect that Zoetis Inc. will post 5.91 EPS for the current year.

Zoetis Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, January 21st will be given a dividend of $0.50 per share. The ex-dividend date of this dividend is Tuesday, January 21st. This is an increase from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a yield of 1.20%. Zoetis’s dividend payout ratio (DPR) is 32.52%.

Wall Street Analyst Weigh In

ZTS has been the subject of several recent research reports. Leerink Partners assumed coverage on shares of Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price for the company. JPMorgan Chase & Co. upped their price objective on shares of Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a report on Friday, October 11th. Leerink Partnrs upgraded Zoetis to a “strong-buy” rating in a report on Monday, December 2nd. UBS Group initiated coverage on Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. One investment analyst has rated the stock with a hold rating, nine have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $211.89.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.